Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aronex Pharma (ARNX) -- Ignore unavailable to you. Want to Upgrade?

To: kendall harmon who wrote (305)	9/27/1999 6:11:00 PM
From: ProfSam	Read Replies (1) \| Respond to of 320

the Reuter's Article quotes an analyst from the Mehta Group and somewhere in his quotes he mentions that there is a chance that ARNX MAY have to go back to clinical trials on Atragen, not just rework the statistical data. There's the pickle, hope he's wrong, first time we've heard this. All this on the same day that Nyotran had a good press release from a presentation at a pharma conference! some bad luck here, Sam